News Quantified

EYPT – eyepoint pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.

3.3%

MISS

5.3%

MISS

3.1%

MISS

5.5%

MISS

Chardan Capital

Chardan Capital

Chardan Capital

Chardan Capital

Form 4 EyePoint Pharmaceuticals For: Mar 19 Filed by: Duker Jay S.

Form 10-K EyePoint Pharmaceuticals For: Dec 31

Form 8-K EyePoint Pharmaceuticals For: Mar 05

Form 8-K EyePoint Pharmaceuticals For: Mar 04

Form SCHEDULE 13G/A EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.

Top News Gainers

1/23 EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues 23.6%

4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%

10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%

4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%

10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%

9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%

3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%

11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%

8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%

11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%

Top News Decliners

11/7 Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.140 ActVsEst (0.010) - Miss -31.1%

2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%

7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%

7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%

11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%

3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%

11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%

4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%

3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%

2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day